Nilotinib Stada

Nilotinib, the active ingredient in Nilotinib Stada, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia in adult patients, targeting disease phases where the BCR‑ABL fusion protein drives malignant cell proliferation.

GNH USA supplies Nilotinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Nilotinib is used in the management of BCR‑ABL positive leukemias, primarily chronic myeloid leukemia.

- Chronic myeloid leukemia (chronic phase): achieves disease control and prolongs survival in patients with the Philadelphia chromosome. - Chronic myeloid leukemia (accelerated phase): reduces disease progression and improves hematologic response. - BCR‑ABL positive leukemias resistant to prior therapy: provides an alternative targeted option when earlier tyrosine kinase inhibitors are ineffective.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools that may require fluid replacement. - Rash: skin eruptions that are usually self‑limited. - Fatigue: generalized tiredness affecting daily activities.

Serious or Rare Side Effects: - QT interval prolongation: may lead to serious cardiac arrhythmias. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Severe hepatic toxicity: significant liver enzyme elevations requiring monitoring.

When prescribing Nilotinib, clinicians should observe several safety considerations to minimize risk.

- Cardiac monitoring: baseline ECG and periodic assessment due to QT prolongation risk. - Liver function tests: monitor hepatic enzymes regularly. - Pancreatic enzymes: check amylase and lipase for signs of pancreatitis. - Concomitant CYP3A4 inhibitors: avoid strong inhibitors that can increase drug exposure. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Nilotinib interacts with several medicines; awareness of the interaction level guides clinical management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase plasma concentrations. - Antacids containing aluminum or magnesium: reduce absorption of nilotinib. - QT‑prolonging agents (e.g., amiodarone, sotalol): additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower nilotinib exposure. - Warfarin: potential alteration of INR, requiring closer monitoring. - St. John’s wort: moderate induction of metabolism, may reduce efficacy.